Entropy Technologies LP Decreases Holdings in Henry Schein, Inc. (NASDAQ:HSIC)

Entropy Technologies LP cut its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 7.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,345 shares of the company’s stock after selling 1,751 shares during the quarter. Entropy Technologies LP’s holdings in Henry Schein were worth $1,408,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. ING Groep NV purchased a new stake in Henry Schein during the 3rd quarter worth $63,226,000. Holocene Advisors LP acquired a new position in shares of Henry Schein in the third quarter worth about $58,319,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Henry Schein in the third quarter valued at about $43,740,000. Southpoint Capital Advisors LP grew its stake in Henry Schein by 30.0% during the 3rd quarter. Southpoint Capital Advisors LP now owns 2,600,000 shares of the company’s stock valued at $189,540,000 after purchasing an additional 600,000 shares in the last quarter. Finally, Bank of Montreal Can grew its stake in Henry Schein by 365.6% during the 3rd quarter. Bank of Montreal Can now owns 711,487 shares of the company’s stock valued at $52,095,000 after purchasing an additional 558,689 shares in the last quarter. 96.62% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Henry Schein

In other news, COO Michael S. Ettinger sold 12,240 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $75.00, for a total value of $918,000.00. Following the completion of the sale, the chief operating officer now directly owns 87,706 shares of the company’s stock, valued at approximately $6,577,950. This represents a 12.25 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.14% of the company’s stock.

Henry Schein Stock Performance

Shares of HSIC stock opened at $78.90 on Tuesday. Henry Schein, Inc. has a 12-month low of $63.67 and a 12-month high of $82.63. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. The firm has a market capitalization of $9.84 billion, a price-to-earnings ratio of 32.47, a price-to-earnings-growth ratio of 2.21 and a beta of 0.91. The business has a 50 day simple moving average of $73.75 and a 200 day simple moving average of $71.86.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Jefferies Financial Group increased their target price on Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, January 23rd. Barrington Research upped their price target on Henry Schein from $82.00 to $90.00 and gave the company an “outperform” rating in a research report on Thursday, January 30th. StockNews.com raised shares of Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Mizuho initiated coverage on shares of Henry Schein in a research report on Wednesday, December 4th. They set a “neutral” rating and a $75.00 price objective for the company. Finally, Bank of America upgraded Henry Schein from an “underperform” rating to a “buy” rating and lifted their target price for the company from $69.00 to $84.00 in a research note on Monday, January 6th. Seven analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $80.10.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.